What 香港中文大学（深圳）医学院 CUHK-Shenzhen MEDICINE does

CUHK-Shenzhen School of Medicine (香港中文大学（深圳）医学院) is a public university medical school established in January 2019 through a trilateral agreement between the Shenzhen Municipal Government, The Chinese University of Hong Kong (CUHK), and CUHK-Shenzhen. It operates as an integral component of CUHK-Shenzhen and is designed to combine CUHK's 140-year medical education heritage with Shenzhen's strategic position in the Greater Bay Area. The school delivers five undergraduate programs (Clinical Medicine, Biomedical Engineering, Bioinformatics, Pharmaceutical Science, and Biological Sciences), plus master's and doctoral programs, with reported graduate outcomes of 96% destination rate and 60% of further-study graduates admitted to top-50 global universities.

The school's research infrastructure is anchored by two Nobel Prize-led institutes — the WARSHEL Computational Biology Institute and the Kobilka Innovative Drug Development Institute — supported by the Kobilka Cryo-Electron Microscopy Center, the KIIDD Advanced Mass Spectrometry Facility, an Experimental Animal Center, and a Biomedical Instrument Sharing Platform. Notable intellectual assets include the internationally recognized miRTarBase microRNA database (8,000+ citations) and dozens of granted patents in biosensors, anti-inflammatory drug targets, and POCT rapid detection. The faculty comprises 650+ globally recruited scholars with overseas experience, including 6 Nobel laureates and 40+ academicians.

Revenue is generated through tuition and fees, government education funding from Shenzhen and Guangdong, research grants from NSFC and provincial/municipal science projects, and — once fully operational — clinical services from the 3,000-bed CUHK-Shenzhen Medical Centre (RMB 5.1B+ capital investment, soft opening Q4 2025, full operation planned 2027). Clinical training is delivered through a network of 10+ affiliated and teaching hospitals across the Greater Bay Area, complemented by international partnerships with UHN, Mount Sinai, Duke-NUS, Weill Cornell, University of Toronto, and Humanitas University. The school received dual accreditation from US and Canadian medical education bodies in 2025, enabling international credentialing of its graduates.

Name

香港中文大学（深圳）医学院 CUHK-Shenzhen MEDICINE

Legal name

香港中文大学（深圳）医学院

Website

https://med.cuhk.edu.cn

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

CUHK-Shenzhen School of Medicine is a public university medical school in Shenzhen, China, founded in 2019 to deliver internationally benchmarked medical education, Nobel-laureate-led biomedical research, and clinical services through a flagship 3,000-bed hospital serving the Greater Bay Area.

Ownership category

akta.pro rank

Product category

Medical Education

NAICS

Colleges, Universities, and Professional Schools (6113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

Keywords

• Medical education
• Clinical training
• Biomedical research
• Pharmaceutical science
• Healthcare services

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Others

Revenue model

1. Tuition and Fees: Revenue from undergraduate and postgraduate tuition fees from students enrolled in clinical medicine, biomedical engineering, bioinformatics, pharmaceutical science, and biological sciences programs.
2. Government Education Funding: Core operational funding from Shenzhen Municipal Government and Guangdong Provincial Government as a publicly funded medical school established under a trilateral agreement (Shenzhen Government, CUHK, CUHK-Shenzhen) signed in January 2019.
3. Research Grants and Contracts: Substantial research funding from national sources including National Natural Science Foundation of China, Guangdong Provincial and Shenzhen Municipal science projects, and international collaborations. Prof. Huang Xianda alone has overseen >10 million RMB in research funding.
4. University Hospital Operations (CUHK-Shenzhen Medical Centre): When fully operational, the 3,000-bed CUHK-Shenzhen Medical Centre (RMB 5.1 billion investment, soft opening Q4 2025) will generate revenue from clinical services, serving as the flagship affiliated teaching hospital.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Core offering

CUHK-Shenzhen School of Medicine delivers undergraduate and postgraduate medical education across five majors (Clinical Medicine, Biomedical Engineering, Bioinformatics, Pharmaceutical Science, Biological Sciences), operates Nobel laureate-led research institutes (Warshel Computational Biology, Kobilka Innovative Drug Development), runs advanced research facilities (Cryo-EM Center, Mass Spectrometry Facility), and provides clinical services through its affiliated 3,000-bed CUHK-Shenzhen Medical Centre and teaching hospital network across the Greater Bay Area.

Product overview

CUHK-Shenzhen School of Medicine is an integrated medical education and healthcare institution combining five undergraduate programs (Clinical Medicine, Biomedical Engineering, Bioinformatics, Pharmaceutical Science, Biological Sciences), postgraduate programs (master's and doctoral levels), Nobel Prize research institutes (WARSHEL Computational Biology, Kobilka Drug Development), advanced research facilities (Cryo-EM Center, Mass Spectrometry Facility, Experimental Animal Center), and affiliated hospitals (3,000-bed Medical Centre, Second Affiliated Hospital). The school also operates a Center for Professionalism and Medical Education Development (CPMED) and maintains clinical teaching bases across the Greater Bay Area. The institution focuses on training medical professionals with international vision while conducting innovative medical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Medicine Undergraduate Program (临床医学) Five-year clinical medicine undergraduate program training medical professionals with international vision and humanistic care, with graduates achieving 96% employment rate and 88.1% pursuing further studies.
• Biomedical Engineering Undergraduate Program (生物医学工程) Interdisciplinary undergraduate program combining engineering principles with medical sciences for medical technology innovation.
• Bioinformatics Undergraduate Program (生物信息学) Interdisciplinary undergraduate program leveraging computational biology and data science to solve life science and medical challenges, supported by the Warshel Nobel Laboratory for Computational Biology.
• Pharmaceutical Science Undergraduate Program (药学) Undergraduate program focusing on drug discovery and design using modern technology including genomics-based drug design, clinical big data applications, and nanomaterials for drug delivery.
• Biological Sciences Undergraduate Program (生物科学) Broad biological sciences undergraduate program covering molecular biology to ecosystem science, designated as a key discipline under Guangdong Province's high-level university initiative.
• Postgraduate Programs (研究生项目) Master's and doctoral programs including Clinical Medicine Philosophy Master's and Doctoral programs, establishing a complete talent cultivation system from undergraduate to postgraduate levels.
• CUHK-Shenzhen Medical Centre (香港中文大学（深圳）医院) 3,000-bed academic health sciences centre with investment exceeding RMB 5.1 billion, featuring key specialties including Critical Care, Cardiovascular, Neurosciences, Oncology, and Organ Transplantation centres. Soft opening commenced Q4 2025 with full operation planned for 2027.
• Second Affiliated Hospital of CUHK-Shenzhen (香港中文大学（深圳）附属第二医院) Affiliated hospital providing clinical teaching and healthcare services, integrated with the medical school for clinical training.
• Center for Professionalism and Medical Education Development (CPMED, 医学教育发展中心) Center focused on medical education professionalism and development, offering training programs including Rain Classroom smart teaching workshops and the S.M.A.R.T center for specialized medical research and training.
• Warshel Institute for Computational Biology (瓦谢尔计算生物研究院) Nobel Prize laureate-led research institute focusing on computational biology, computer-aided drug design, genomic sequences, and biomolecular structural research, supporting the Bioinformatics program.
• Kobilka Institute for Innovative Drug Development (科比尔卡创新药物开发研究院) Nobel Prize laureate-led institute advancing innovative drug development research and pharmaceutical science.
• Kobilka Cryo-Electron Microscopy Center (冷冻电镜中心) State-of-the-art cryo-EM facility providing single particle reconstruction and 2D characterization services for molecular structural biology research and drug discovery.
• KIIDD Advanced Mass Spectrometry Facility Advanced mass spectrometry facility supporting proteomics, metabolomics, and drug discovery research for the medical school and external collaborators.

Quantifiable outcome

• 96% graduate employment/destination rate
• +7 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

20 partnerships are on record, tiered major and core.

• Humanitas University (Italy)majorStrategic or Co-development Partner · 1 June 2026CUHK-Shenzhen MED signed an MOU with Humanitas University for strategic cooperation, announced in June 2026, further expanding the school's European academic network.
• CUHK Medical Centre (Hong Kong)coreStrategic or Co-development Partner · 1 September 2022Strategic cooperation framework agreement signed between CUHK-Shenzhen and CUHK Medical Centre for joint medical education, research collaboration, and clinical services, leveraging CUHK's 140-year medical heritage.
• Longgang District Government, ShenzhencoreStrategic or Co-development Partner · 1 October 2021Cooperation agreement signed with Longgang District Government for the joint construction of an affiliated hospital, serving the healthcare needs of the Longgang District and Greater Bay Area.
• Shanghai Sixth People's Hospital (上海市第六人民医院)coreStrategic or Co-development Partner · 22 April 2021The first teaching hospital of CUHK-Shenzhen. A strategic cooperation framework agreement was signed on April 22, 2021, covering frontier scientific research, affiliated hospital construction, medical education and teaching, medical discipline construction, and medical treatment services.
• Shenzhen Municipal GovernmentcoreStrategic or Co-development Partner · 1 January 2019Trilateral agreement signed in January 2019 between Shenzhen Municipal Government, CUHK, and CUHK-Shenzhen to jointly establish the CUHK-Shenzhen School of Medicine and its affiliated hospitals, as part of the Greater Bay Area and Shenzhen Pilot Demonstration Area development strategy.
• University Health Network (UHN), CanadamajorStrategic or Co-development PartnerInternational partnership with UHN, an internationally recognized academic health sciences center affiliated with the University of Toronto, encompassing four hospitals. Toronto General Hospital was ranked #4 among the World's Top 10 Hospitals by Newsweek in 2020 and ranked first on Canada's Top 40 Research Hospitals list for 2018.
• Mount Sinai Health System, USAmajorStrategic or Co-development PartnerInternational partnership with Mount Sinai Health System, a major healthcare institution with 8 hospital campuses and the Icahn School of Medicine at Mount Sinai, dedicated to advancing innovative, high-quality healthcare globally.
• Duke-NUS Medical School, SingaporemajorStrategic or Co-development PartnerInternational partnership with Duke-NUS Medical School, established through collaboration between Duke University and the National University of Singapore, providing innovative education and impactful research that enhances the practice of medicine in Singapore and beyond.
• Weill Cornell Medicine, USAmajorStrategic or Co-development PartnerInternational partnership with Weill Cornell Medicine, one of the top medical schools in the United States, founded in 1898 with an educational philosophy of integrating strong medical science foundation with comprehensive clinical training.
• University of Toronto, CanadamajorStrategic or Co-development PartnerInternational partnership with the University of Toronto, Canada's top university founded in 1827, known for research-intensive excellence and a community of 680,000+ graduates advancing impact globally.
• Peking University Shenzhen HospitalcoreStrategic or Co-development PartnerClinical teaching base; a modern comprehensive public 3A hospital founded in 1999, covering 59,000 sqm with 1,778 open beds. Ranked 59th among top 100 hospitals in China with A+ grade for two consecutive years.
• Shenzhen Children's HospitalcoreStrategic or Co-development PartnerClinical teaching base; the only 3A pediatric hospital in Guangdong Province, established in 1997, covering 43,000 sqm with 1,277 beds. Ranked 8th nationally among pediatric hospitals in the 2019 tertiary public hospital performance appraisal.
• Shenzhen Nanshan People's HospitalcoreStrategic or Co-development PartnerClinical teaching base; a 3A comprehensive hospital established by Nanshan Government. Ranked 110th out of 1,183 public comprehensive hospitals nationally, top 4 in Shenzhen, and listed 43rd among the best 80 hospitals in the Greater Bay Area.
• Shenzhen Baoan Women's and Children's HospitalcoreStrategic or Co-development PartnerClinical teaching base; a Class A tertiary specialized hospital with 830 beds and 1,600+ employees, including 282 senior professionals and 54 doctoral degree holders. Has led Shenzhen in number of births for three consecutive years (2019-2021).
• University of Hong Kong-Shenzhen HospitalcoreStrategic or Co-development PartnerClinical teaching base; a major comprehensive public hospital with 2,000 beds (expanding to 3,000), total floor area of 367,000 sqm on 192,000 sqm of land, with a total capital cost of about RMB 4 billion.
• Joint Shantou International Eye Center of Shantou University and CUHKcoreStrategic or Co-development PartnerClinical teaching base; the only non-profit Class 3A eye hospital directly under the Guangdong Province Health Commission, ranked 2nd in specialty reputation (ophthalmology) among hospitals in Southern China for 8 consecutive years.
• Shenzhen Longgang E.N.T HospitalcoreStrategic or Co-development PartnerClinical teaching base; the only Class 3 ENT specialty hospital in Shenzhen, established in 2009, with 100 beds. Has established the Shenzhen ENT Research Institute, Longgang Stomatology Research Institute, and joint research centers with CUHK and McMaster University.
• Shenzhen New Frontier United Family HospitalcoreStrategic or Co-development PartnerClinical teaching base; a comprehensive hospital with 135 beds, approximately 73,000 sqm building area, providing internationally aligned, high-quality health management and medical services following JCI international standards.
• Guangdong Jiaoersheng Pharmaceutical Technology Co., Ltd. (广东健尔圣医药科技有限公司)majorStrategic or Co-development PartnerIndustry-academia-research partnership for innovative drug development. Jointly developed GMDTC, the world's first specific antidote for cadmium poisoning, with results published in Clinical Pharmacology & Therapeutics. The company provided proprietary transmembrane drug technology for cellular entry and exit of chelating agents.
• Kobilka Cryo-Electron Microscopy Center PartnersmajorTechnology or IntegrationCryo-EM facility providing high-resolution structural biology services to researchers, with established protocols and workflows for single-particle cryo-EM reconstruction and 2D characterization.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Duke-NUS Medical School: A joint medical school between Duke University and the National University of Singapore. Direct model comparator: combines US-style medical education with Asian context, focuses on physician-scientists, and has strong translational research orientation.
• West China School of Medicine (Sichuan University): One of China's top medical schools, recognized for clinical excellence, large affiliated hospital, and broad medical research portfolio. Comparable in scale and ambition across clinical medicine, pharmaceutical science, and biomedical research.
• Zhejiang University School of Medicine: Top-tier Chinese medical school with strong biomedical engineering, pharmaceutical sciences, and clinical medicine programs. Comparable in combining multiple life science disciplines with large affiliated hospital networks.
• Tsinghua University School of Medicine: Another relatively new elite Chinese medical school with strong research emphasis and partnerships with international institutions. Similar model combining top-tier research faculty, affiliated hospitals, and bilingual/dual-degree programs targeting world-class medical training in China.
• Peking University Health Science Center: One of China's oldest and most prestigious medical schools, with extensive affiliated hospital network, strong research output, and deep residency placement track record. Represents the top-tier incumbent the school must compete with for faculty and top students.
• Shanghai Jiao Tong University School of Medicine: One of China's strongest research-oriented medical schools, with internationally recognized affiliated hospitals (e.g., Ruijin, Renji) and significant cross-border research collaborations. Sets the standard for integrated medical research and clinical training in China.
• Fudan University Shanghai Medical College: One of China's top medical schools, integrating research-intensive medical education with major affiliated teaching hospitals. Sets the benchmark for academic medical centers that CUHK-Shenzhen Med aims to emulate in clinical medicine and biomedical sciences.
• Sun Yat-sen University Medical School: Leading medical school in Southern China with strong GBA presence, broad affiliated hospital network, and significant biomedical research. Closest geographic and clinical peer in the Guangdong-Hong Kong-Macao Greater Bay Area.

Regional players

• Southern Medical University: Major medical university headquartered in Guangzhou with strong footprint across the GBA, including large affiliated hospitals. Regional peer competing for GBA students, faculty, and clinical training resources.

Emerging players

• Weill Cornell Medicine - Qatar: Branch campus of Weill Cornell Medicine offering US-style MD training outside the US. Relevant model peer for CUHK-Shenzhen Med in demonstrating how to deliver internationally benchmarked medical education in a non-US jurisdiction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CUHKSZ_MED
• Facebookfacebook.com/CUHKSZMED
• LinkedInlinkedin.com/company/%E9%A6%99%E6%B8%AF%E4%B8%AD%E6%96%87%E5%A4%A7%E5%AD%A6%EF%BC%88%E6%B7%B1%E5%9C%B3%EF%BC%89%E5%8C%BB%E5%AD%A6%E9%99%A2-cuhk-shenzhen-medicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 香港中文大学（深圳）医学院 CUHK-Shenzhen MEDICINE